{"content":"<li class=\"n-box-item date-title\" data-end=\"1500091199\" data-start=\"1500004800\" data-txt=\"Monday, December 23, 2019\">Friday, July 14, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3278816\" data-ts=\"1500072183\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRCO\" target=\"_blank\">TRCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278816-tribune-media-holder-sues-to-block-sinclair-buyout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tribune Media holder sues to block Sinclair buyout</a></h4><ul>   <li>A shareholder in Tribune Media (<a href=\"http://seekingalpha.com/symbol/TRCO\" target=\"_blank\">TRCO</a> <font color='green'>+0.8%</font>) is <a href=\"http://www.fiercecable.com/broadcasting/tribune-shareholder-files-suit-to-block-sinclair-acquisition\" target=\"_blank\">suing in an effort to block</a> an acquisition of the company by Sinclair Broadcast Group (<a href=\"http://seekingalpha.com/symbol/SBGI\" target=\"_blank\">SBGI</a> <font color='green'>+1.8%</font>), the country's biggest local TV station owner.</li>    <li>Sean McEntire accuses Tribune of not providing all financial projections or how much other bidders may have offered for the company before it <a href=\"https://seekingalpha.com/news/3264552-sinclair-broadcast-announces-3_9b-deal-tribune-media\" target=\"_blank\">agreed to a $3.9B buyout</a>.</li>    <li>He's seeking class action status.</li>    <li>Meanwhile, Senate Democrats are looking for a special hearing on the deal, which will create a local broadcast giant, and the FCC continues to work on <a href=\"https://seekingalpha.com/news/3273784-tribune-media-sinclair-gain-court-allows-fcc-ownership-rule\" target=\"_blank\">reinstating the \"UHF Discount\"</a> that would ease ownership rules and is likely critical to the Sinclair-Tribune deal.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278816\" data-linked=\"Tribune Media holder sues to block Sinclair buyout\" data-tweet=\"$TRCO $TRCO $SBGI - Tribune Media holder sues to block Sinclair buyout https://seekingalpha.com/news/3278816-tribune-media-holder-sues-to-block-sinclair-buyout?source=tweet\" data-url=\"https://seekingalpha.com/news/3278816-tribune-media-holder-sues-to-block-sinclair-buyout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278806\" data-ts=\"1500068123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278806-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+6.3%</font>. <a href='https://seekingalpha.com/symbol/CGI' title='Celadon Group, Inc.'>CGI</a> <font color='green'>+3.1%</font>. <a href='https://seekingalpha.com/symbol/CSTM' title='Constellium Holdco B.V.'>CSTM</a> <font color='green'>+1.9%</font>. <a href='https://seekingalpha.com/symbol/EPZM' title='Epizyme'>EPZM</a> <font color='green'>+1.8%</font>. <a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a> <font color='green'>+1.5%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> PPHM <font color='red'>-16.5%</font>. <a href='https://seekingalpha.com/symbol/ERA' title='Era Group Inc.'>ERA</a> <font color='red'>-2.3%</font>. FSC <font color='red'>-1.9%</font>. <a href='https://seekingalpha.com/symbol/SQNS' title='Sequans Communications'>SQNS</a> <font color='red'>-1.8%</font>. <a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a> <font color='red'>-1.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278806\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$ACRX $CGI $CSTM - After Hours Gainers / Losers https://seekingalpha.com/news/3278806-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3278806-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>140&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278800\" data-ts=\"1500065763\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYES\" target=\"_blank\">EYES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278800-medicare-reimbursement-for-second-sights-argus-may-drop-19-next-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medicare reimbursement for Second Sight&#39;s Argus may drop 19% next year</a></h4><ul><li>The U.S. Centers for Medicare &amp; Medicaid Services &#40;CMS&#41; has <a href=\"https://seekingalpha.com/filing/3626026\" target=\"_blank\">proposed </a>a new reimbursement code for Second Sight Medical's (NASDAQ:<a href='https://seekingalpha.com/symbol/EYES' title='Second Sight Medical Products'>EYES</a>) Argus II Retinal Prosthesis System in 2018 that would, if enacted, reduce reimbursement to ~$122K from $150K this year.</li><li>The company says it will comment on the proposed change to CMS in the coming months. The final rule will be released in mid-Q4.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278800\" data-linked=\"Medicare reimbursement for Second Sight&#39;s Argus may drop 19% next year\" data-tweet=\"$EYES - Medicare reimbursement for Second Sight&#39;s Argus may drop 19% next year https://seekingalpha.com/news/3278800-medicare-reimbursement-for-second-sights-argus-may-drop-19-next-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3278800-medicare-reimbursement-for-second-sights-argus-may-drop-19-next-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278793\" data-ts=\"1500064632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDMO\" target=\"_blank\">CDMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278793-peregrine-fiscal-q4-top-line-down-5-eps-down-140-shares-down-13-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Peregrine fiscal Q4 top line down 5%; EPS down 140%; shares down 13% after hours</a></h4><ul><li>Peregrine Pharmaceuticals (PPHM) fiscal <a href=\"https://seekingalpha.com/pr/16887353-peregrine-pharmaceuticals-reports-financial-results-quarter-fiscal-year-ended-april-30-2017\" target=\"_blank\">Q4 results</a> ($M): Contract manufacturing revenue: 17.9 (-4.8%); Net Loss: (6.7) (+49.6%); Loss/share: (0.16) (-140.0%).</li><li>Four new customers signed, expected to contribute to to revenues in fiscal 2018.</li><li>Three process validation studies completed. Revenue upside when customers build inventory and commence commercial launch.</li><li>Three clinical trials with NCCN proceeding as planned.</li><li><strong>2018 Guidance</strong>: Manufacturing revenue: &nbsp;$50M - 55M.</li><li>Shares are down 13% after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278793\" data-linked=\"Peregrine fiscal Q4 top line down 5%; EPS down 140%; shares down 13% after hours\" data-tweet=\"$CDMO - Peregrine fiscal Q4 top line down 5%; EPS down 140%; shares down 13% after hours https://seekingalpha.com/news/3278793-peregrine-fiscal-q4-top-line-down-5-eps-down-140-shares-down-13-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3278793-peregrine-fiscal-q4-top-line-down-5-eps-down-140-shares-down-13-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278792\" data-ts=\"1500064400\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278792-weekly-etf-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weekly ETF Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/GAZ' title='iPath DJ-UBS Natural Gas Total Return Sub-Index ETN'>GAZ</a> <font color='green'>+13.1%</font>. <a href='https://seekingalpha.com/symbol/EWZ' title='iShares MSCI Brazil Capped ETF'>EWZ</a> <font color='green'>+8.1%</font>. <a href='https://seekingalpha.com/symbol/BRF' title='VanEck Vectors Brazil Small-Cap ETF'>BRF</a> <font color='green'>+7.0%</font>. <a href='https://seekingalpha.com/symbol/ILF' title='iShares Latin America 40 ETF'>ILF</a> <font color='green'>+6.9%</font>. <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a> <font color='green'>+6.3%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/VXX' title='iPath S&P 500 VIX Short-Term Futures ETN'>VXX</a> <font color='red'>-8.1%</font>. <a href='https://seekingalpha.com/symbol/UUP' title='PowerShares DB USD Bull ETF'>UUP</a> <font color='red'>-0.9%</font>. <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a> <font color='red'>-0.5%</font>. <a href='https://seekingalpha.com/symbol/PGF' title='PowerShares Financial Preferred Portfolio ETF'>PGF</a> <font color='red'>-0.4%</font>. <a href='https://seekingalpha.com/symbol/KBWD' title='PowerShares KBW High Dividend Yield Financial Portfolio ETF'>KBWD</a> <font color='red'>-0.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278792\" data-linked=\"Weekly ETF Gainers / Losers\" data-tweet=\"$GAZ-OLD $EWZ $BRF - Weekly ETF Gainers / Losers https://seekingalpha.com/news/3278792-weekly-etf-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3278792-weekly-etf-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278773\" data-ts=\"1500061775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NWS\" target=\"_blank\">NWS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278773-rosenblatt-starts-news-corp-buy-on-real-estate-strength\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rosenblatt starts News Corp. at Buy on real-estate strength</a></h4><ul>   <li>Rosenblatt Securities has launched coverage of News Corp. (<a href='https://seekingalpha.com/symbol/NWS' title='News Corporation'>NWS</a> <font color='green'>+2%</font>, <a href='https://seekingalpha.com/symbol/NWSA' title='News Corporation'>NWSA</a> <font color='green'>+2.8%</font>) at Buy on the thesis that what looks like an old-line publisher has a <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/07/9778495/news-corp-is-a-digital-real-estate-play-wrapped-inside-a\" target=\"_blank\">hidden real-estate heart</a>.</li>    <li>More than half its noncash value is tied up in its digital real-estate portfolio, says analyst Alan Gould, with more than 60% of the value in digital real estate and cash.</li>    <li>The company's been adding several acquisitions into new media and has cash for more, he argues, even while it looks to scale back some older-media properties. It's now a \"digital real estate play wrapped inside a newspaper company.\"</li>    <li>He has a NWSA price target of $17, implying 25% upside from today's higher price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278773\" data-linked=\"Rosenblatt starts News Corp. at Buy on real-estate strength\" data-tweet=\"$NWS $NWS $NWSA - Rosenblatt starts News Corp. at Buy on real-estate strength https://seekingalpha.com/news/3278773-rosenblatt-starts-news-corp-buy-on-real-estate-strength?source=tweet\" data-url=\"https://seekingalpha.com/news/3278773-rosenblatt-starts-news-corp-buy-on-real-estate-strength\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278771\" data-ts=\"1500059748\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPS\" target=\"_blank\">GPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278771-gap-named-top-specialty-retail-pick-j-p-morgan-sharesplus-10-in-two-days\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gap named top specialty retail pick at J.P. Morgan; shares +10% in two days</a></h4><ul>     <li>Gap (<a href='https://seekingalpha.com/symbol/GPS' title='The Gap, Inc.'>GPS</a> <font color='green'>+2.3%</font>) is added to J.P. Morgan's Analyst Focus List as the firm's <a href=\"http://www.cnbc.com/2017/07/14/jpmorgan-makes-gap-a-top-retail-pick.html\" target=\"_blank\">top specialty retail idea</a>, saying the stock's near-term risk/reward is \"too hard to ignore,\" trading at 4x EBITDA with a 4% dividend and 8% free cash flow yield.</li><li>\"Our recent fieldwork points to signs of more stable footing at the Old  Navy concept with encouraging underlying signs pointing to core Gap  product,\" JPM's Matthew Boss writes.</li><li>GPS surged 5.6% <a href=\"https://seekingalpha.com/news/3278472-retailers-recovery-mode-improved-target-guidance\" target=\"_blank\">yesterday</a> as the <a href=\"http://www.barrons.com/articles/the-hot-stock-gap-gains-5-6-1499978310\" target=\"_blank\">S&amp;P 500's top gainer</a> after Target's improved guidance lifted retailers; shares have jumped 10% during the two days.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278771\" data-linked=\"Gap named top specialty retail pick at J.P. Morgan; shares +10% in two days\" data-tweet=\"$GPS - Gap named top specialty retail pick at J.P. Morgan; shares +10% in two days https://seekingalpha.com/news/3278771-gap-named-top-specialty-retail-pick-j-p-morgan-sharesplus-10-in-two-days?source=tweet\" data-url=\"https://seekingalpha.com/news/3278771-gap-named-top-specialty-retail-pick-j-p-morgan-sharesplus-10-in-two-days\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278766\" data-ts=\"1500058805\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278766-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corp.'>TCCO</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/POLA' title='Polar Power Inc'>POLA</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SQNS' title='Sequans Communications'>SQNS</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/YY' title='YY Inc.'>YY</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ATEN' title='A10 Networks, Inc.'>ATEN</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/CYBR' title='CyberArk Software Ltd.'>CYBR</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/HLIT' title='Harmonic Inc.'>HLIT</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CBAK-OLD' title='China BAK Battery, Inc.'>CBAK-OLD</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/LEDS' title='SemiLEDs Corporation'>LEDS</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278766\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$TCCO $POLA $NTNX - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3278766-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3278766-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278763\" data-ts=\"1500057567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278763-will-wont-rumored-defection-of-astrazeneca-chief-soriot-to-teva-may-not-be-fait-accompli-teva\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Will he or won&#39;t he? Rumored defection of AstraZeneca chief Soriot to Teva may not be a fait accompli; Teva down 4%, AZN up 4%</a></h4><ul><li>Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color='red'>-4.2%</font>) retraces a good bit of its past two-day rally on more than a 50% spike in volume while AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='green'>+3.9%</font>) regains much of its recent drop, also on higher volume. The stocks initially moved in opposite directions on the news that AZN CEO Pascal Soriot would take the top spot at Teva but many <a href=\"https://www.wsj.com/articles/mystery-at-astrazeneca-is-ceo-pascal-soriot-staying-or-going-1499945355\" target=\"_blank\">observers </a>believe that he may stay put.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3278285-teva-tap-astrazenecas-soriot-new-chief\" target=\"_blank\">Teva to tap AstraZeneca's Soriot as new chief</a> (July 12)</li><li><strong>Update</strong>: Bloomberg reports that informed sources say Mr. Soriot will remain at AZN.</li><li><strong>Update</strong>: Mr. Soriot is scheduled to participate in the company's Q2 results presentation on July 27 <a href=\"https://endpts.com/pascal-soriot-is-staying-at-astrazeneca-after-all-turning-down-a-big-offer-from-teva-report/\" target=\"_blank\">reports</a> John Carroll.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278763\" data-linked=\"Will he or won&#39;t he? Rumored defection of AstraZeneca chief Soriot to Teva may not be a fait accompli; Teva down 4%, AZN up 4%\" data-tweet=\"$TEVA $TEVA $AZN - Will he or won&#39;t he? Rumored defection of AstraZeneca chief Soriot to Teva may not be a fait accompli; Teva down 4%, AZN up 4% https://seekingalpha.com/news/3278763-will-wont-rumored-defection-of-astrazeneca-chief-soriot-to-teva-may-not-be-fait-accompli-teva?source=tweet\" data-url=\"https://seekingalpha.com/news/3278763-will-wont-rumored-defection-of-astrazeneca-chief-soriot-to-teva-may-not-be-fait-accompli-teva\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278761\" data-ts=\"1500056778\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278761-pareteumplus-7-sees-extension-on-nyse-compliance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +7%; sees extension on NYSE compliance</a></h4><ul>   <li>Comms technology firm Pareteum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) is moving up again today, <font color='green'>+7%</font>, after noting it's gotten an <a href=\"https://seekingalpha.com/pr/16887166-pareteum-granted-extension-nyse-mkt-compliance-listing-requirements\" target=\"_blank\">extension from the NYSE</a> in order to get in compliance with listing requirements.</li>    <li>The company got an NYSE notice yesterday saying it's not yet in compliance with four of its listing standards, while it has complied with a fifth.</li>    <li>The due date for compliance on the four standards is now uniform at November 27.</li>    <li>\"Having completed our restructuring in 2016, Pareteum is proving its value and potential in the market through our $60 million contracted backlog, which we expect will convert into growing quarterly revenues,\" says Chairman Hal Turner. \"Combined with our cost-cutting measures, we are positioned to meet our listing requirement obligations.\"</li>    <li>Shares in the stock <font color='green'>rose 134%</font> on Tuesday after the company posted <a href=\"https://seekingalpha.com/news/3277946-pareteum-stock-nearly-doubles-upbeat-q2-numbers\" target=\"_blank\">upbeat preliminary earnings numbers</a> for its Q2.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278761\" data-linked=\"Pareteum +7%; sees extension on NYSE compliance\" data-tweet=\"$TEUM - Pareteum +7%; sees extension on NYSE compliance https://seekingalpha.com/news/3278761-pareteumplus-7-sees-extension-on-nyse-compliance?source=tweet\" data-url=\"https://seekingalpha.com/news/3278761-pareteumplus-7-sees-extension-on-nyse-compliance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278760\" data-ts=\"1500055932\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRK.A\" target=\"_blank\">BRK.A</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278760-sprintplus-3_5-on-report-of-approaching-buffett-malone-for-investment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprint +3.5% on report of approaching Buffett, Malone for investment</a></h4><ul>   <li>Sprint (<a href=\"http://seekingalpha.com/symbol/S\" target=\"_blank\">S</a> <font color='green'>+3.5%</font>) is spiking higher on word that its executives have <a href=\"https://www.wsj.com/articles/sprint-executives-have-engaged-warren-buffett-about-investment-1500055560\" target=\"_blank\">engaged with Warren Buffett and John Malone</a> about investing in the company.</li>    <li>Sprint Chairman Masayoshi Son met with the two (separately) in Sun Valley, Idaho, about taking part in a potential deal.</li><li>One possibility <em>The Wall Street Journal</em> notes is Berkshire Hathaway&nbsp;(<a href='https://seekingalpha.com/symbol/BRK.A' title='Berkshire Hathaway A'>BRK.A</a>, <a href='https://seekingalpha.com/symbol/BRK.B' title='Berkshire Hathaway B'>BRK.B</a>) putting more than $10B into a deal.</li>     <li>Malone's a heavy investor in Charter (NASDAQ:<a href='https://seekingalpha.com/symbol/CHTR' title='Charter Communications, Inc.'>CHTR</a>) through Liberty Broadband (NASDAQ:<a href='https://seekingalpha.com/symbol/LBRDA' title='Liberty Broadband Corporation'>LBRDA</a>), and Charter and Comcast entered into an exclusive <a href=\"https://seekingalpha.com/news/3275622-wsj-sprint-exploring-wireless-deal-charter-comcast\" target=\"_blank\">two-month discussion window</a> with Sprint to see how they might re-sell wireless service.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278760\" data-linked=\"Sprint +3.5% on report of approaching Buffett, Malone for investment\" data-tweet=\"$BRK.A $BRK.A $BRK.B - Sprint +3.5% on report of approaching Buffett, Malone for investment https://seekingalpha.com/news/3278760-sprintplus-3_5-on-report-of-approaching-buffett-malone-for-investment?source=tweet\" data-url=\"https://seekingalpha.com/news/3278760-sprintplus-3_5-on-report-of-approaching-buffett-malone-for-investment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>309&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278758\" data-ts=\"1500055226\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278758-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/RIC' title='Richmont Mines, Inc'>RIC</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/CELP' title='Cypress Energy Partners, L.P.'>CELP</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/HOS' title='Hornbeck Offshore Services, Inc.'>HOS</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/OEC' title='Orion Engineered Carbons'>OEC</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/DDC' title='Dominion Diamond Corporation'>DDC</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/MNGA' title='MagneGas Corporation'>MNGA</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278758\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$RIC $CELP $HOS - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3278758-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3278758-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278743\" data-ts=\"1500052489\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XON\" target=\"_blank\">XON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278743-intrexon-down-2-on-competition-for-oxitecs-mosquitoes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intrexon down 2% on competition for Oxitec&#39;s mosquitoes</a></h4><ul><li>Intrexon (<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a> <font color='red'>-1.7%</font>) has been dropped from the market's in-the-green peloton. The culprit appears to be the first field study of sterile male <em>Aedes aegypti</em> mosquitoes in Fresno, CA by <a href=\"https://verily.com/\" target=\"_blank\">Verily Life Sciences</a>. The initiative, called the <a href=\"https://blog.verily.com/2017/07/debug-fresno-our-first-us-field-study.html\" target=\"_blank\">Debug Project</a>, will assess the disease control method over a 20-week period in two neighborhoods each ~300 acres in size.</li><li>Intrexon's Oxitec unit has the same aim with OX513A. Its largest project to date is in Brazil. Studies are also underway in the Cayman Islands, Florida's <a href=\"http://www.businessinsider.com/scientists-sex-mosquitos-florida-fight-zika-2017-5\" target=\"_blank\">Key Haven</a> and India.</li><li>Verily's method involves treating sterile male <em>A. aegypti</em> mosquitoes with a bacterium called <em>Wolbachia </em>which interferes with female mosquitoes' reproduction. No genetic engineering is required.</li><li>Oxitec's OX513A bugs are genetically engineered so that offspring inherit a gene that causes death before reaching reproductive age.</li><li>It's too early to tell which approach will be more effective, cost efficient and scalable.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3186456-oxitec-expands-mosquito-control-program-brazil\" target=\"_blank\">Oxitec expands mosquito control program in Brazil</a> (May 31, 2016)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3180204-grand-cayman-signs-use-oxitecs-ox513a-suppress-disease-spreading-mosquitoes\" target=\"_blank\">Grand Cayman signs up to use Oxitec's OX513A to suppress disease-spreading  mosquitoes</a> (May 5, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3278743\" data-linked=\"Intrexon down 2% on competition for Oxitec&#39;s mosquitoes\" data-tweet=\"$XON - Intrexon down 2% on competition for Oxitec&#39;s mosquitoes https://seekingalpha.com/news/3278743-intrexon-down-2-on-competition-for-oxitecs-mosquitoes?source=tweet\" data-url=\"https://seekingalpha.com/news/3278743-intrexon-down-2-on-competition-for-oxitecs-mosquitoes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278745\" data-ts=\"1500051610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278745-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> FSC <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='green'>+11%</font>.FSFR <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/MLP' title='Maui Land & Pineapple Company, Inc.'>MLP</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/FSAM' title='Fifth Street Asset Management Inc.A'>OTCPK:FSAM</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278745\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$OCSL $PN $OCSI - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3278745-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3278745-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278741\" data-ts=\"1500050424\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278741-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CGI' title='Celadon Group, Inc.'>CGI</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/DAC' title='Danaos Corporation'>DAC</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+16%</font>. FSC <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/CTSO' title='Cytosorbents Corp'>CTSO</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/NURO' title='NeuroMetrix, Inc.'>NURO</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/MLP' title='Maui Land & Pineapple Company, Inc.'>MLP</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/ATEN' title='A10 Networks, Inc.'>ATEN</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/CYBR' title='CyberArk Software Ltd.'>CYBR</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/NVGS' title='Navigator Holdings Ltd.'>NVGS</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CBAK-OLD' title='China BAK Battery, Inc.'>CBAK-OLD</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/HLIT' title='Harmonic Inc.'>HLIT</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/NHTC' title='Natural Health Trends Corp.'>NHTC</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278741\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$CGI $EIGR $DAC - Midday Gainers / Losers https://seekingalpha.com/news/3278741-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3278741-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278740\" data-ts=\"1500049876\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDC\" target=\"_blank\">DDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278740-reuters-dominion-diamond-in-buyout-talks-washington-companies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Dominion Diamond in buyout talks with Washington Companies</a></h4><ul>     <li>Dominion Diamond (<a href='https://seekingalpha.com/symbol/DDC' title='Dominion Diamond Corporation'>DDC</a> <font color='green'>+6%</font>) spikes on a Reuters report that it is <a href=\"http://www.reuters.com/article/us-dominion-diamond-m-a-washingtoncompan-idUSKBN19Z1VO\" target=\"_blank\">in advanced talks to be acquired</a> by privately held Washington Companies.</li>     <li>Negotiations are focused on the two sides settling on a price, with a deal possibly ready to be announced within weeks, according to the report.</li>     <li>It is not clear how much Washington had increased its initial unsolicited $13.50/share proposal, which was the catalyst for DDC to formally put itself up for sale in March.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278740\" data-linked=\"Reuters: Dominion Diamond in buyout talks with Washington Companies\" data-tweet=\"$DDC - Reuters: Dominion Diamond in buyout talks with Washington Companies https://seekingalpha.com/news/3278740-reuters-dominion-diamond-in-buyout-talks-washington-companies?source=tweet\" data-url=\"https://seekingalpha.com/news/3278740-reuters-dominion-diamond-in-buyout-talks-washington-companies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278736\" data-ts=\"1500048090\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278736-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/BETR' title='Amplify Snack Brands'>BETR</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods'>ANFI</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/WPRT' title='Westport Fuel Systems, Inc.'>WPRT</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/NHTC' title='Natural Health Trends Corp.'>NHTC</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/CRWS' title='Crown Crafts, Inc.'>CRWS</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278736\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$BETR-OLD $ANFI $REED - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3278736-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3278736-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278735\" data-ts=\"1500047934\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MLCO\" target=\"_blank\">MLCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278735-casino-stocks-slide-on-junket-operator-warning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Casino stocks slide on junket operator warning</a></h4><ul>     <li>Macau gaming stocks are under pressure following reports of junket  liquidity issues in Macau and potentially strict regulations in Japan  casinos: <a href='https://seekingalpha.com/symbol/MLCO' title='Melco Resorts & Entertainment Limited ADR'>MLCO</a> <font color='red'>-3.1%</font>, <a href='https://seekingalpha.com/symbol/WYNN' title='Wynn Resorts, Limited'>WYNN</a> <font color='red'>-2.8%</font>, <a href='https://seekingalpha.com/symbol/LVS' title='Las Vegas Sands Corp.'>LVS</a> <font color='red'>-1.7%</font>, <a href='https://seekingalpha.com/symbol/MGM' title='MGM Resorts International'>MGM</a> <font color='red'>-0.9%</font>.</li>     <li>A large junket operator in Macau reportedly has <a href=\"http://thefly.com/landingPageNews.php?id=2578391&amp;headline=MGM;WYNN;LVS;MLCO-Macau-gaming-names-slide-after-Daiwa-uncovers-junket-operator-warning\" target=\"_blank\">warned about  liquidity risk</a> in the face of continued anti-money laundering  initiatives by regulators.</li>     <li>The junket operator advised its customers to withdraw funds out of \"underground\" bank  accounts, according to Daiwa analyst Jamie Soo.</li><li>A top prosecutor in Macau has been found <a href=\"http://www.investors.com/news/corruption-crackdown-in-macau-sends-casino-stocks-down/\" target=\"_blank\">guilty of corruption</a>, as the Chinese government continues a crackdown in the gambling district.</li>     <li>Also, Bloomberg reports that Japan is <a href=\"https://www.bloomberg.com/view/articles/2017-07-14/japan-may-cripple-its-casinos\" target=\"_blank\">considering strict regulations</a> for potential casino projects expected in the coming years.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278735\" data-linked=\"Casino stocks slide on junket operator warning\" data-tweet=\"$MLCO $MLCO $WYNN - Casino stocks slide on junket operator warning https://seekingalpha.com/news/3278735-casino-stocks-slide-on-junket-operator-warning?source=tweet\" data-url=\"https://seekingalpha.com/news/3278735-casino-stocks-slide-on-junket-operator-warning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278733\" data-ts=\"1500047807\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAOI\" target=\"_blank\">AAOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278733-susquehanna-applied-opto-results-good-omen-for-corning\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Susquehanna: Applied Opto results a good omen for Corning</a></h4><ul>   <li>Susquehanna has reiterated its positive take on Corning (<a href=\"http://seekingalpha.com/symbol/GLW\" target=\"_blank\">GLW</a> <font color='green'>+0.3%</font>), noting that a <a href=\"https://seekingalpha.com/news/3278443-applied-optoelectronics-plus-7-percent-strong-early-q2-results\" target=\"_blank\">healthy pre-announcement</a> of earnings numbers from Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) <a href=\"http://www.barrons.com/articles/corning-applied-optos-pre-announce-a-nice-sign-says-susquehanna-1500046008\" target=\"_blank\">bodes well for the fiber supplier</a>.</li>    <li>Applied Opto is again on the move today, <font color='green'>up 7.3%</font>.</li>    <li>The AAOI announcement indicates \"continued strength in GLW's optical communications biz unit,&rdquo; writes analyst Mehdi Hosseini, \"specifically, AAOI's top line revenue has a 79% correlation to GLW's carrier sub-segment (2013-current).\"</li>    <li>AAOI said its revenue would come in at $117.3M, beating earlier forecasts for $106M-$112M.</li>    <li>Corning may pursue M&amp;A as well to hit its 2020 revenue goals, Hosseini says, with an eye toward \"opportunities with product sets that are complementary to GLW's current offerings, as a means of enabling the company to sell a service versus just miles of fiber.</li>    <li>\"Whereas fiber used to be laid for long haul, now we see an increasing number of short/dense deployments (even just meters in length),\" Hosseini says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278733\" data-linked=\"Susquehanna: Applied Opto results a good omen for Corning\" data-tweet=\"$AAOI $AAOI $GLW - Susquehanna: Applied Opto results a good omen for Corning https://seekingalpha.com/news/3278733-susquehanna-applied-opto-results-good-omen-for-corning?source=tweet\" data-url=\"https://seekingalpha.com/news/3278733-susquehanna-applied-opto-results-good-omen-for-corning\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278727\" data-ts=\"1500045065\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JPM\" target=\"_blank\">JPM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278727-analysts-weigh-in-on-jpms-downward-guidance-for-net-interest-income\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts weigh in on JPM&#39;s downward guidance for net interest income</a></h4><ul>     <li>JPMorgan Chase (<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a> <font color='red'>-1.2%</font>) earned $26.5B over the past 12 months, <a href=\"https://www.bloomberg.com/news/articles/2017-07-14/jpmorgan-proves-wall-street-bank-profits-don-t-depend-on-traders\" target=\"_blank\">the most ever by any major U.S. bank</a>, but its decision to guide lower its full-year outlook for net interest income is a factor <a href=\"https://blogs.wsj.com/moneybeat/2017/07/14/j-p-morgan-wells-fargo-and-citi-report-2q-earnings-live-analysis/\" target=\"_blank\">weighing on the stock</a>.</li>     <li>Buckingham Research's James Mitchell: &ldquo;NII was below forecast, with JPM guiding to NII growth this year of +$4B vs. +$4.5B previously. This likely reflects the impact of a flattening yield curve and lower NII in trading. So while NII growth is still quite positive, the lower guide is an incremental negative.&rdquo;</li>     <li>Instinet's Steven Chubak: &ldquo;While 2Q results are encouraging, we expect shares to come under some pressure... The company guided to lower NII for FY&rsquo;17 as well as weaker core loan growth (+8% Y/Y, vs. prior guidance of +10%), suggesting 2H NII forecasts may be too high.\"</li>     <li>Keefe Bruyette &amp; Woods' Brian Kleinhanzl: &ldquo;JPM lowered the full-year NII increase [and net interest margins] came in below our expectation and declined from 1Q17... However, loan growth came in better than our expectations and management&rsquo;s guidance on credit is better than our forecast.&rdquo;</li>     <li><a href=\"https://seekingalpha.com/news/3278653-jpm-tilts-red-solid-earnings-beat\" target=\"_blank\">Q2 earnings</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3278727\" data-linked=\"Analysts weigh in on JPM&#39;s downward guidance for net interest income\" data-tweet=\"$JPM - Analysts weigh in on JPM&#39;s downward guidance for net interest income https://seekingalpha.com/news/3278727-analysts-weigh-in-on-jpms-downward-guidance-for-net-interest-income?source=tweet\" data-url=\"https://seekingalpha.com/news/3278727-analysts-weigh-in-on-jpms-downward-guidance-for-net-interest-income\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278714\" data-ts=\"1500044464\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278714-healthcare-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/AXON' title='Axovant Sciences'>AXON</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/NURO' title='NeuroMetrix, Inc.'>NURO</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/CARA' title='Cara Therapeutics Inc.'>CARA</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/CVM' title='Cel-Sci Corporation'>CVM</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278714\" data-linked=\"Healthcare Gainers / Losers as of 11:00 am\" data-tweet=\"$EIGR $EKSO $AXON-OLD - Healthcare Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3278714-healthcare-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3278714-healthcare-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278722\" data-ts=\"1500043817\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ULTA\" target=\"_blank\">ULTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278722-ulta-beauty-on-move-goldman-upgrades-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ulta Beauty on the move as Goldman upgrades to Buy</a></h4><ul>     <li>Ulta Beauty (<a href='https://seekingalpha.com/symbol/ULTA' title='Ulta Beauty, Inc.'>ULTA</a> <font color='green'>+1.9%</font>) moves higher after Goldman Sachs <a href=\"http://www.marketwatch.com/story/ulta-beauty-shares-rise-after-goldman-upgrade-2017-07-14\" target=\"_blank\">upgrades shares to Buy</a> from Neutral with a $310 price target, saying it is positive after the recent selloff and citing \"sector-leading\" same-store sales growth.</li>     <li>While Amazon is a powerful competitor, Goldman does not not believe that increased price competition from AMZN and other retailers will derail Ulta's \"core value proposition or that Amazon yet offers a compelling alternative to the consumer.\"</li>     <li>Goldman analysts \"expect continued share gains, reflecting incremental sales captured from department stores, upside from the rollout of new brands and boutiques, and growth in Ulta's membership program, also a powerful source of valuable data.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3278722\" data-linked=\"Ulta Beauty on the move as Goldman upgrades to Buy\" data-tweet=\"$ULTA - Ulta Beauty on the move as Goldman upgrades to Buy https://seekingalpha.com/news/3278722-ulta-beauty-on-move-goldman-upgrades-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3278722-ulta-beauty-on-move-goldman-upgrades-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278703\" data-ts=\"1500038809\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNSL\" target=\"_blank\">CNSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278703-consolidated-communicationsminus-2_8-on-report-of-3_7m-share-secondary\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consolidated Communications -2.8% on report of 3.7M-share secondary</a></h4><ul>   <li>Consolidated Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/CNSL' title='Consolidated Communications Holdings, Inc.'>CNSL</a>) is <font color='red'>off 2.8%</font> premarket on a report from Bloomberg that it's expected to offer 3.7M shares in secondary offering.</li>    <li>The shares are reportedly coming at $17.75 each; Consolidated closed at $18.42 yesterday and are quoting at $17.90 before today's session.</li>    <li>Shares are <font color='red'>down 31.4%</font> YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278703\" data-linked=\"Consolidated Communications -2.8% on report of 3.7M-share secondary\" data-tweet=\"$CNSL - Consolidated Communications -2.8% on report of 3.7M-share secondary https://seekingalpha.com/news/3278703-consolidated-communicationsminus-2_8-on-report-of-3_7m-share-secondary?source=tweet\" data-url=\"https://seekingalpha.com/news/3278703-consolidated-communicationsminus-2_8-on-report-of-3_7m-share-secondary\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278702\" data-ts=\"1500038599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROV\" target=\"_blank\">TROV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278702-trovagene-commences-direct-equity-offering-shares-down-18-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trovagene commences direct equity offering; shares down 18% premarket</a></h4><ul><li>Nano cap Trovagene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) is down&nbsp;<font color='red'>18%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16887081-trovagene-announces-7_1-million-registered-direct-offering\" target=\"_blank\">announcement </a>of a direct offering of ~6.2M shares of common stock and warrants to purchase ~4.6M shares of common for a combined price of $1.15 to accredited investors.</li><li>The five-year warrants are exercisable at $1.41 per common share. Closing date is July 19.</li><li>Yesterday's close was $1.41.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278702\" data-linked=\"Trovagene commences direct equity offering; shares down 18% premarket\" data-tweet=\"$TROV - Trovagene commences direct equity offering; shares down 18% premarket https://seekingalpha.com/news/3278702-trovagene-commences-direct-equity-offering-shares-down-18-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3278702-trovagene-commences-direct-equity-offering-shares-down-18-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278700\" data-ts=\"1500038502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACIA\" target=\"_blank\">ACIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278700-acacia-communicationsminus-6_1-preliminary-q2-misses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acacia Communications -6.1% as preliminary Q2 misses</a></h4><ul>   <li>Acacia Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a>) is <font color='red'>off 6.1%</font> premarket after noting preliminary earnings results that substantially <a href=\"https://seekingalpha.com/pr/16886964-acacia-communications-announces-preliminary-second-quarter-2017-results\" target=\"_blank\">miss expectations</a>, attributed to a previously announced issue at a contract manufacturer.</li>    <li>The company noted preliminary second-quarter revenues of $77M-$79M vs. an expected $91.3M, and EPS of $0.17-$0.20 vs. $0.32 expected.</li>    <li>\"As we previously announced, we identified a circuit board cleaning process as the likely root cause of the quality issue,\" says CEO Raj Shanmugaraj. \"This cleaning process was eliminated and manufacturing at the impacted contract manufacturer resumed.\"</li>    <li>The company expects to finish remediation on the issue in Q3.</li>    <li>Looking to Q3, the company expects revenue of $95M-$110M (vs. consensus for $108M) and non-GAAP EPS of $0.25-$0.40 (below consensus for $0.47).</li>    <li>The company named a <a href=\"https://seekingalpha.com/pr/16886972-acacia-communications-expands-executive-team-new-vp-sales\" target=\"_blank\">new VP of sales</a>, Eric Fisher, who led Americas sales teams and global key accounts at Intel. He succeeds John LoMedico, who will continue as VP of Business Development.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278700\" data-linked=\"Acacia Communications -6.1% as preliminary Q2 misses\" data-tweet=\"$ACIA - Acacia Communications -6.1% as preliminary Q2 misses https://seekingalpha.com/news/3278700-acacia-communicationsminus-6_1-preliminary-q2-misses?source=tweet\" data-url=\"https://seekingalpha.com/news/3278700-acacia-communicationsminus-6_1-preliminary-q2-misses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278698\" data-ts=\"1500038383\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278698-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li>FSC <font color='green'>+17%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3278663-fifth-street-finance-19-percent-deal-oaktree-assume-management\" target=\"_blank\">deal</a> for Oaktree to assume management.</li>     <li><a href='https://seekingalpha.com/symbol/HPJ' title='Highpower International, Inc.'>HPJ</a> <font color='green'>+10%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a> <font color='green'>+9%</font>&nbsp;on European marketing <a href=\"https://seekingalpha.com/news/3278655-ctis-european-marketing-application-pacritinib-certain-myelofibrosis-patients-accepted-review\" target=\"_blank\">application</a> for pacritinib in certain myelofibrosis patients accepted for review.</li>     <li><a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a> <font color='green'>+8%</font>&nbsp;as Goldman Sachs makes a <a href=\"https://seekingalpha.com/news/3278672-nutanix-moved-conviction-list-goldman-sachs-shares-6-percent-premarket\" target=\"_blank\">buy rating</a> with a $31 PT.</li>     <li><a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+7%</font>. as Jefferies rates stock with a <a href=\"https://seekingalpha.com/news/3278688-jefferies-likes-acelrx-pharma-sees-three-bagger-shares-7-percent-premarket\" target=\"_blank\">buy</a> target of $7.</li>     <li><a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a> <font color='green'>+6%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/PTX' title='Pernix Therapeutics Holdings, Inc.'>PTX</a> <font color='green'>+5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278698\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$OCSL $HPJ $CTIC - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3278698-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3278698-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278695\" data-ts=\"1500038114\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278695-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/CYBR' title='CyberArk Software Ltd.'>CYBR</a>&nbsp;<font color='red'>-19%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3278568-cyberark-drops-q2-revenue-preview-ceo-disappointed-shares-nearly-18-percent\" target=\"_blank\">lowering</a> preliminary Q2 revenue range.</li><li><a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a> <font color='red'>-17%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16887081-trovagene-announces-7_1-million-registered-direct-offering\" target=\"_blank\">announcing</a> $7.1M registered direct offering.</li><li><a href='https://seekingalpha.com/symbol/ATEN' title='A10 Networks, Inc.'>ATEN</a>&nbsp;<font color='red'>-17%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16886660-a10-networks-announces-preliminary-second-quarter-2017-financial-results\" target=\"_blank\">lowering</a> Q2 guidance.</li><li><a href='https://seekingalpha.com/symbol/SHLO' title='Shiloh Industries, Inc.'>SHLO</a> <font color='red'>-7%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16886872-shiloh-industries-inc-announces-pricing-common-stock-offering\" target=\"_blank\">pricing</a> common stock offering.</li><li><a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a> <font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16886964-acacia-communications-announces-preliminary-second-quarter-2017-results\" target=\"_blank\">announcing</a> preliminary Q2 results.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3278695\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$CYBR $TROV $ATEN - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3278695-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3278695-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278692\" data-ts=\"1500037513\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WMT\" target=\"_blank\">WMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278692-wal-martplus-1_6-goldman-upgrades-adds-to-conviction-buy-list\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wal-Mart +1.6% as Goldman upgrades, adds to Conviction Buy List</a></h4><ul>     <li>Wal-Mart (NYSE:<a href='https://seekingalpha.com/symbol/WMT' title='Walmart Inc.'>WMT</a>) <font color='green'>+1.6%</font> premarket after Goldman Sachs <a href=\"http://www.marketwatch.com/story/wal-mart-shares-up-16-premarket-as-goldman-upgrades-to-buy-and-adds-to-conviction-list-2017-07-14\" target=\"_blank\">upgrades shares to Buy</a> from Neutral with an $84 price target, up from $78, and adds to its Conviction List, saying WMT is \"as well positioned as any mass market retailer\" to cope with increasing demands of e-commerce and technology spending, and weather Amazon&rsquo;s growth</a>.</li><li>\"We see merits in WMT's front-loaded investment, scale, capacity for  additional investment, small-market focus, and current impressive  inventory discipline,\" the firm writes.</li><li>Other positives include WMT&rsquo;s \"excellent working capital management,\" bottoming of food inflation, improved return on capital, and&nbsp;relative price/earnings ratio is below the multi-year mean.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278692\" data-linked=\"Wal-Mart +1.6% as Goldman upgrades, adds to Conviction Buy List\" data-tweet=\"$WMT - Wal-Mart +1.6% as Goldman upgrades, adds to Conviction Buy List https://seekingalpha.com/news/3278692-wal-martplus-1_6-goldman-upgrades-adds-to-conviction-buy-list?source=tweet\" data-url=\"https://seekingalpha.com/news/3278692-wal-martplus-1_6-goldman-upgrades-adds-to-conviction-buy-list\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278691\" data-ts=\"1500037391\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYBR\" target=\"_blank\">CYBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278691-analyst-downgrades-and-pt-slashes-follow-cyberarks-preliminary-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analyst downgrades and PT slashes follow CyberArk&#39;s preliminary Q2 results</a></h4><ul><li>        JPMorgan downgrades CyberArk (NASDAQ:<a href='https://seekingalpha.com/symbol/CYBR' title='CyberArk Software Ltd.'>CYBR</a>) from Neutral to Overweight and slashes the price target from $63 to $45.</li><li>               Analyst Sterling Autry cites issues in EMEA execution that surfaced in Q1, drove a large part of the miss, and could take up to a year to correct.&nbsp;&nbsp;</li><li>               Stephens puts the company&rsquo;s rating at Equal Weight from Overweight and cuts the price target from $60 to $42.&nbsp;</li><li>               Analyst Johnathan Ruykhaver notes that the EMEA trouble and declining growth in U.S. might indicate a lack of market demand for CyberArk solutions, a problem that&rsquo;s particularly concerning with the increases in sales and marketing spending.&nbsp;</li><li>                  Cowen has CyberArk at Market Perform and drops the price target by $10 to $43.&nbsp;    </li><li>               Analyst Gregg Moskowitz says EMEA weakness backed by longer sales cycles that caused Q2 to end without the closure of several large deals.&nbsp;</li><li>               Source: Bloomberg.&nbsp;</li><li>               CyberArk shares are&nbsp;<font color='red'>down 18.76%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3278568-cyberark-drops-q2-revenue-preview-ceo-disappointed-shares-nearly-18-percent\" target=\"_blank\">CyberArk drops Q2 revenue in preview, CEO \"disappointed\"; shares down nearly 18%</a> (July 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3278691\" data-linked=\"Analyst downgrades and PT slashes follow CyberArk&#39;s preliminary Q2 results\" data-tweet=\"$CYBR - Analyst downgrades and PT slashes follow CyberArk&#39;s preliminary Q2 results https://seekingalpha.com/news/3278691-analyst-downgrades-and-pt-slashes-follow-cyberarks-preliminary-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3278691-analyst-downgrades-and-pt-slashes-follow-cyberarks-preliminary-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278688\" data-ts=\"1500037049\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACRX\" target=\"_blank\">ACRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278688-jefferies-likes-acelrx-pharma-sees-three-bagger-shares-up-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies likes AcelRx Pharma, sees more than a three-bagger; shares up 7% premarket</a></h4><ul><li>Nano cap AcelRx Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a>) is up&nbsp;<font color='green'>7%</font>&nbsp;premarket on light volume on the heels of <a href=\"https://www.streetinsider.com/New+Coverage/Jefferies+Assumes+AcelRx+Pharmaceuticals+%28ACRX%29+at+Buy/13098286.html\" target=\"_blank\">new coverage</a> by Jefferies. Analyst Matt Andrews rates the stock a Buy with a $7 (226% upside) price target.</li><li>The company's U.S. marketing application for pain med DSUVIA is currently under FDA review. The action date is October 12.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3246654-fda-accepts-acelrxs-nda-pain-med-arxminus-04-action-date-october-12-shares-ahead-7-percent\" target=\"_blank\">FDA accepts AcelRx's NDA for pain med ARX-04; action date October 12; shares ahead 7% premarket</a> (Feb. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3278688\" data-linked=\"Jefferies likes AcelRx Pharma, sees more than a three-bagger; shares up 7% premarket\" data-tweet=\"$ACRX - Jefferies likes AcelRx Pharma, sees more than a three-bagger; shares up 7% premarket https://seekingalpha.com/news/3278688-jefferies-likes-acelrx-pharma-sees-three-bagger-shares-up-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3278688-jefferies-likes-acelrx-pharma-sees-three-bagger-shares-up-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278686\" data-ts=\"1500036655\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WFC\" target=\"_blank\">WFC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278686-wells-fargo-slides-q2-earnings-beat-estimates-revenues-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells Fargo slides as Q2 earnings beat estimates, revenues miss</a></h4><ul><li>Wells Fargo (NYSE:<a href='https://seekingalpha.com/symbol/WFC' title='Wells Fargo & Co.'>WFC</a>) <font color='red'>-1.7%</font> premarket as <a href=\"https://seekingalpha.com/news/3278666-wells-fargo-beats-0_06-misses-revenue\" target=\"_blank\">Q2 earnings</a> beat expectations but revenue came in on the light side.</li><li>Net interest income increased  $183M Q/Q to $12.5B, lower than the $12.8B analyst consensus estimate; net interest margin 2.90%, up 3 bps from Q1.</li><li>Total average deposits were $1.3T, up 5% Y/Y, and total average loans were $957B, up 1%.</li><li>Return on assets 1.21%; return on equity 11.95%.</li><li>Costs rose 5.2% Y/Y to $13.5B from $12.9B in the year-ago quarter; expenses as a share of revenue was 61.1%, <a href=\"https://www.wsj.com/articles/wells-fargo-posts-stronger-than-expected-earnings-1500033880\" target=\"_blank\">slightly above the new target</a> of 60%-61% set in May and higher than the  two-year target set last year of 55%-59%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278686\" data-linked=\"Wells Fargo slides as Q2 earnings beat estimates, revenues miss\" data-tweet=\"$WFC - Wells Fargo slides as Q2 earnings beat estimates, revenues miss https://seekingalpha.com/news/3278686-wells-fargo-slides-q2-earnings-beat-estimates-revenues-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3278686-wells-fargo-slides-q2-earnings-beat-estimates-revenues-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278685\" data-ts=\"1500036556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDXG\" target=\"_blank\">MDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278685-mimedx-group-announces-q2-revenue-results-shares-ahead-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MiMedx Group announces Q2 revenue results; shares ahead 7% premarket</a></h4><ul> <li>MiMedx Group (<a href='https://seekingalpha.com/symbol/MDXG' title='MiMedx Group Inc.'>OTC:MDXG</a>) <a href=\"https://seekingalpha.com/pr/16886690-c-o-r-r-e-c-t-o-n-mimedx-group-inc\" target=\"_blank\">announces</a> its Q2 revenue results.</li> <li>Q2 revenue of $76.4M exceeding guidance range of $73.5 to $75M.</li><li>Q2 revenue grew 33%, an increase of $19.1M over Q2 2016 revenue of $57.3M.</li><li>First six months revenue grew 35% to $149M over 1H 2016 revenue of $110.7M.</li>    <li>The Company plans to release its Q2 full results on July 27 and will also provide Q3 revenue guidance.</li><li>Shares are up&nbsp;<font color='green'>7%</font>&nbsp;premarket on light volume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3278685\" data-linked=\"MiMedx Group announces Q2 revenue results; shares ahead 7% premarket\" data-tweet=\"$MDXG - MiMedx Group announces Q2 revenue results; shares ahead 7% premarket https://seekingalpha.com/news/3278685-mimedx-group-announces-q2-revenue-results-shares-ahead-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3278685-mimedx-group-announces-q2-revenue-results-shares-ahead-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278682\" data-ts=\"1500036096\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOC\" target=\"_blank\">BIOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278682-biocept-launches-liquid-biopsy-test-for-progesterone-receptor-shares-ahead-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biocept launches liquid biopsy test for progesterone receptor; shares ahead 5% premarket</a></h4><ul><li>Nano cap Biocept (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a>) is up&nbsp;<font color='green'>5%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16887021-biocept-expands-commercial-offering-clinically-actionable-biomarker-assays-launch-liquid\" target=\"_blank\">announcement</a> of the commercial availability of its new liquid biopsy test for progesterone receptor &#40;PR&#41;, a biomarker in the blood for breast cancer.</li><li>SVP and Medical Director Veena Singh, M.D. says, \"The ability to detect PR expression in circulating tumor cells (CTCs) complements Biocept's existing ER and HER2 assays for biomarker analysis in breast cancer. With the addition of PR detection using our high sensitivity CTC platform, we offer liquid biopsy assays for all NCCN Guideline&reg;-based biomarkers pertinent to the care of patients with breast cancer.\"</li><li>The company performs its testing services from its CLIA-certified laboratory in San Diego.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278682\" data-linked=\"Biocept launches liquid biopsy test for progesterone receptor; shares ahead 5% premarket\" data-tweet=\"$BIOC - Biocept launches liquid biopsy test for progesterone receptor; shares ahead 5% premarket https://seekingalpha.com/news/3278682-biocept-launches-liquid-biopsy-test-for-progesterone-receptor-shares-ahead-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3278682-biocept-launches-liquid-biopsy-test-for-progesterone-receptor-shares-ahead-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278676\" data-ts=\"1500035332\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EIGR\" target=\"_blank\">EIGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278676-btig-likes-eiger-bio-sees-four-bagger-shares-ahead-11-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BTIG likes Eiger Bio, sees a four-bagger; shares ahead 11% premarket</a></h4><ul><li>Thinly traded nano cap Eiger BioPharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a>) is up&nbsp;<font color='green'>11%</font>&nbsp;premarket on light volume. This morning BTIG initiated coverage with a Buy rating and $32 price target (330% upside).</li><li>Analyst Robert Hazlett says multiple catalysts are ahead including Phase 2 data on ubenimex in pulmonary arterial hypertension.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3278676\" data-linked=\"BTIG likes Eiger Bio, sees a four-bagger; shares ahead 11% premarket\" data-tweet=\"$EIGR - BTIG likes Eiger Bio, sees a four-bagger; shares ahead 11% premarket https://seekingalpha.com/news/3278676-btig-likes-eiger-bio-sees-four-bagger-shares-ahead-11-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3278676-btig-likes-eiger-bio-sees-four-bagger-shares-ahead-11-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278672\" data-ts=\"1500034493\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTNX\" target=\"_blank\">NTNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278672-nutanix-moved-to-conviction-list-goldman-sachs-shares-up-6-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nutanix moved to conviction list at Goldman Sachs; shares up 6% premarket</a></h4><ul><li>        Goldman Sachs adds Nutanix (NASDAQ:<a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a>) to its conviction list. The firm has a Buy rating on the company with a $31 price target.</li><li>               Analyst Simona Jankowski calls Nutanix a &ldquo;once-in-a-decade tech infrastructure story.&rdquo;&nbsp;</li><li>               Jankowski notes that a new accounting method could push Nutanix revenues above consensus estimates by 12% to 13% in FY18 and FY19.&nbsp;</li><li>Source: Bloomberg. </li><li>               Nutanix shares are&nbsp;<font color='green'>up 6.07%</font>&nbsp;premarket.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3278672\" data-linked=\"Nutanix moved to conviction list at Goldman Sachs; shares up 6% premarket\" data-tweet=\"$NTNX - Nutanix moved to conviction list at Goldman Sachs; shares up 6% premarket https://seekingalpha.com/news/3278672-nutanix-moved-to-conviction-list-goldman-sachs-shares-up-6-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3278672-nutanix-moved-to-conviction-list-goldman-sachs-shares-up-6-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278668\" data-ts=\"1500033851\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JUNO\" target=\"_blank\">JUNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278668-juno-reportedly-preparing-7m-share-offeringminus-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Juno reportedly preparing 7M-share offering, -2% premarket</a></h4><ul><li>Juno Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/JUNO' title='Juno Therapeutics'>JUNO</a>) slips&nbsp;<font color='red'>2%</font>&nbsp;premarket on light volume. According to Bloomberg, it is about to announce a 7M-share stock offering.</li><li><strong>Update</strong>: The company is apparently shopping a 7M-share block trade at $27.40.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278668\" data-linked=\"Juno reportedly preparing 7M-share offering, -2% premarket\" data-tweet=\"$JUNO - Juno reportedly preparing 7M-share offering, -2% premarket https://seekingalpha.com/news/3278668-juno-reportedly-preparing-7m-share-offeringminus-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3278668-juno-reportedly-preparing-7m-share-offeringminus-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278663\" data-ts=\"1500033438\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OAK\" target=\"_blank\">OAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278663-fifth-street-finance-up-19-on-deal-for-oaktree-to-assume-management\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fifth Street Finance up 19% on deal for Oaktree to assume management</a></h4><ul><li>Under the deal, Oaktree (NYSE:<a href='https://seekingalpha.com/symbol/OAK' title='Oaktree Capital Group'>OAK</a>) will replace Fifth Street Asset Management (<a href='https://seekingalpha.com/symbol/FSAM' title='Fifth Street Asset Management Inc.A'>OTCPK:FSAM</a>) as the investment adviser for Fifth Street Finance (FSC) and Fifth Street Senior Floating Rate (FSFR).</li><li>FSAM will receive $320M in cash from Oaktree at closing, and intends to make an initial distribution to its shareholders of $2.75 in cash, and seek approval for further distributions.</li><li>Once Oaktree takes over, the management fee for FSC will be cut 25 basis points to 1.50%, and the incentive fee 250 basis points to 17.5%. The 1% management fee at FSFR stays the same, but its incentive fee will also be cut to 17.5% from 20%.</li><li>All of the management teams at both companies will be replaced with Oaktree people, as will the boards (with the exception of one person at each company).</li><li>The deal is expected to close in Q4.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16886966-fifth-street-asset-management-inc-enters-agreement-oaktree-assume-management-business\" target=\"_blank\">Press Release</a></li><li>FSC&nbsp;<font color='green'>+19%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3278663\" data-linked=\"Fifth Street Finance up 19% on deal for Oaktree to assume management\" data-tweet=\"$OAK $OAK $FSAM - Fifth Street Finance up 19% on deal for Oaktree to assume management https://seekingalpha.com/news/3278663-fifth-street-finance-up-19-on-deal-for-oaktree-to-assume-management?source=tweet\" data-url=\"https://seekingalpha.com/news/3278663-fifth-street-finance-up-19-on-deal-for-oaktree-to-assume-management\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278655\" data-ts=\"1500032776\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTIC\" target=\"_blank\">CTIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278655-ctis-european-marketing-application-for-pacritinib-in-certain-myelofibrosis-patients-accepted\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CTI&#39;s European marketing application for pacritinib in certain myelofibrosis patients accepted for review; shares ahead 10% premarket</a></h4><ul><li>Thinly traded nano cap CTI BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a>) perks up&nbsp;<font color='green'>10%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16886609-cti-biopharma-announces-european-medicines-agency-validation-pacritinib-marketing\" target=\"_blank\">announcement </a>that the European Medicines Agency &#40;EMA&#41; has validated its Marketing Authorization Application &#40;MAA&#41; seeking approval of pacritinib for the treatment of myelofibrosis patients who have thrombocytopenia (low blood platelets).</li><li>The review clock by the EMA's Committee for Medicinal Products for Human Use &#40;CHMP&#41; is 210 days, excluding question or opinion response periods.</li><li>Pacritinib is an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. The JAK family of enzymes plays a key role in normal blood cell growth and development, immune responses and the expression of proinflammatory cytokines.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278655\" data-linked=\"CTI&#39;s European marketing application for pacritinib in certain myelofibrosis patients accepted for review; shares ahead 10% premarket\" data-tweet=\"$CTIC - CTI&#39;s European marketing application for pacritinib in certain myelofibrosis patients accepted for review; shares ahead 10% premarket https://seekingalpha.com/news/3278655-ctis-european-marketing-application-for-pacritinib-in-certain-myelofibrosis-patients-accepted?source=tweet\" data-url=\"https://seekingalpha.com/news/3278655-ctis-european-marketing-application-for-pacritinib-in-certain-myelofibrosis-patients-accepted\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278657\" data-ts=\"1500032433\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGI\" target=\"_blank\">CGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278657-celadonplus-15-after-selecting-svindland-new-ceo-will-to-retire\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celadon +15% after selecting Svindland as new CEO; Will to retire</a></h4><ul>     <li>Celadon (NYSE:<a href='https://seekingalpha.com/symbol/CGI' title='Celadon Group, Inc.'>CGI</a>) <font color='green'>+14.9%</font>&nbsp;premarket after appointing Paul Svindland as its <a href=\"https://seekingalpha.com/pr/16886623-celadon-group-announces-executive-team-changes\" target=\"_blank\">new CEO</a> effective on or about July 24, succeeding Paul WIll, who is retiring as CEO and Chairman.</li>     <li>Svindland, currently Chairman and CEO of Farren International Holdings, a P-E backed holding company for multiple trucking companies, is considered a turnaround specialist.</li>          <li>Svindland tells <em>WSJ</em> that he plans to <a href=\"https://www.wsj.com/articles/celadon-hires-turnaround-expert-1499989185\" target=\"_blank\">focus on CGI&rsquo;s asset-based trucking business</a>, which he says is fundamentally strong but in recent years had lacked discipline.</li><li>Michael Miller, chairman of CGI&rsquo;s compensation committee, will serve as Chairman during the search for a new board chair.</li></ul><div class=\"tiny-share-widget\" data-id=\"3278657\" data-linked=\"Celadon +15% after selecting Svindland as new CEO; Will to retire\" data-tweet=\"$CGI - Celadon +15% after selecting Svindland as new CEO; Will to retire https://seekingalpha.com/news/3278657-celadonplus-15-after-selecting-svindland-new-ceo-will-to-retire?source=tweet\" data-url=\"https://seekingalpha.com/news/3278657-celadonplus-15-after-selecting-svindland-new-ceo-will-to-retire\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3278645\" data-ts=\"1500030024\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JPM\" target=\"_blank\">JPM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3278645-jpmorgan-chase-beats-0_24-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan Chase beats by $0.24, beats on revenue</a></h4><ul><li>JPMorgan Chase (NYSE:<a href='https://seekingalpha.com/symbol/JPM' title='JPMorgan Chase & Co.'>JPM</a>): Q2 EPS of $1.82 <font color='green'>beats by $0.24</font>.</li><li>Revenue of $25.5B (+1.2% Y/Y) <font color='green'>beats by $1.1B</font>.</li><li>Shares <font color='green'>+1.5%</font> PM.</li><li><a href=\"https://www.jpmorganchase.com/corporate/investor-relations/document/2Q17_Earnings_Press_Release.pdf\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3278645\" data-linked=\"JPMorgan Chase beats by $0.24, beats on revenue\" data-tweet=\"$JPM - JPMorgan Chase beats by $0.24, beats on revenue https://seekingalpha.com/news/3278645-jpmorgan-chase-beats-0_24-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3278645-jpmorgan-chase-beats-0_24-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":40,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}